2025 European LeukemiaNet recommendations for the management of chronic myeloid leukemia
Fu’s Subcutaneous Needling Combined with Kinematic Acupuncture versus Electroacupuncture in the Treatment of Cervical Spondylotic Radiculopathy: A Randomized Controlled Trial
Dynamic culture system advances the applications of breast cancer organoids for precision medicine
The Role of the PI3K/Akt/mTOR Axis in Head and Neck Squamous Cell Carcinoma
Poria cocos polysaccharide alleviates dextran sulphate sodium-induced ulcerative colitis in mice by modulating intestinal inflammatory responses and microbial dysbiosis
A predictive model for therapy failure in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy
Comparison of the Efficacy Among Nilotinib, Dasatinib, Flumatinib and Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia Patients: A Real-World Multi-Center Retrospective Study
Efficacy, safety, and survival findings after <scp>long‐term</scp> follow‐up of <scp>ZGJAK002</scp>: A phase 2 study comparing jaktinib at 100 mg twice daily (<scp>BID</scp>) and 200 mg once daily (<scp>QD</scp>) in patients with myelofibrosis
CACA guidelines for holistic integrative management of adult acute myeloid leukemia
Evaluation of gecacitinib vs hydroxyurea in patients with intermediate-2 or high-risk myelofibrosis: final analysis results from a randomized phase 3 study
Post Hoc Analysis of Phase III Gecacitinib Clinical Trial Outcomes: Enhanced Understanding and Implications
Variables Associated with Outcomes in Patients with Chronic Neutrophilic Leukemia with <i>CSF3RT618I</i> : A Multi-Centre Retrospective Study
A life-threatening bleeding prediction model for immune thrombocytopenia based on personalized machine learning: a nationwide prospective cohort study
A randomized, double-blind, phase 3 study of jaktinib versus hydroxyurea (HU) in patients (pts) with intermediate-2 or high-risk myelofibrosis (MF).
S212: A RANDOMIZED DOUBLE-BLIND PHASE 3 STUDY OF JAKTINIB VERSUS HYDROXYUREA IN PATIENTS WITH INTERMEDIATE-2 OR HIGH RISK MYELOFIBROSIS
Validation of the imatinib-therapy failure model
[To compare the efficacy and incidence of severe hematological adverse events of flumatinib and imatinib in patients newly diagnosed with chronic phase chronic myeloid leukemia].
Imatinib compared with second‐generation tyrosine kinase‐inhibitors in persons with chronic myeloid leukemia presenting in accelerated phase
Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial
Safety and efficacy of jaktinib in the treatment of Janus kinase <scp>inhibitor‐naïve</scp> patients with myelofibrosis: Results of a phase <scp>II</scp> trial
GIGYF1 disruption associates with autism and impaired IGF-1R signaling
Electrochemical Reduction and Oxidation of Chlorinated Aromatic Compounds Enhanced by the Fe-ZSM-5 Catalyst: Kinetics and Mechanisms
Developing and validating a mortality prediction model for ICH in ITP: a nationwide representative multicenter study
Genome assembly of the Chinese maize elite inbred line RP125 and its EMS mutant collection provide new resources for maize genetics research and crop improvement
Prediction of postpartum hemorrhage in pregnant women with immune thrombocytopenia: Development and validation of the <scp>MONITOR</scp> model in a nationwide multicenter study
Variables associated with patient-reported outcomes in patients with myeloproliferative neoplasms
Risk stratification and outcomes of intracranial hemorrhage in patients with immune thrombocytopenia under 60 years of age
A risk score for predicting hospitalization for community-acquired pneumonia in ITP using nationally representative data
Folate deficiency facilitates recruitment of upstream binding factor to hot spots of DNA double-strand breaks of rRNA genes and promotes its transcription
Asia-Pacific Hematology Consortium Report on approach to multiple myeloma. Survey results from the 6th International Hematologic Malignancies Conference: Bridging the Gap 2015, Beijing, China